Your browser is no longer supported. Please, upgrade your browser.
SGMO Sangamo Therapeutics, Inc. daily Stock Chart
Sangamo Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own0.30% Shs Outstand138.98M Perf Week-2.69%
Market Cap1.50B Forward P/E- EPS next Y-0.98 Insider Trans0.00% Shs Float116.09M Perf Month10.50%
Income-101.60M PEG- EPS next Q-0.24 Inst Own56.30% Short Float18.39% Perf Quarter-2.34%
Sales111.40M P/S13.48 EPS this Y-20.40% Inst Trans0.54% Short Ratio13.33 Perf Half Y29.05%
Book/sh3.68 P/B2.95 EPS next Y12.50% ROA-14.70% Target Price- Perf Year25.03%
Cash/sh4.80 P/C2.26 EPS next 5Y- ROE-23.10% 52W Range4.81 - 13.20 Perf YTD29.51%
Dividend- P/FCF23.53 EPS past 5Y-16.60% ROI-24.30% 52W High-17.88% Beta2.08
Dividend %- Quick Ratio7.20 Sales past 5Y17.40% Gross Margin- 52W Low125.36% ATR0.50
Employees354 Current Ratio7.20 Sales Q/Q23.40% Oper. Margin-98.70% RSI (14)53.85 Volatility4.35% 4.78%
OptionableYes Debt/Eq0.00 EPS Q/Q2.40% Profit Margin-91.20% Rel Volume0.51 Prev Close10.65
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume1.60M Price10.84
Recom2.10 SMA204.83% SMA502.20% SMA20016.37% Volume815,378 Change1.78%
Sep-08-20Initiated BofA Securities Buy $20
Jul-07-20Initiated SunTrust Buy $22
Aug-26-19Initiated H.C. Wainwright Buy $16
Nov-14-18Downgrade JP Morgan Overweight → Neutral
Nov-09-18Downgrade Guggenheim Buy → Neutral
Oct-10-18Initiated Guggenheim Buy
Jun-20-18Initiated BofA/Merrill Buy $24
Nov-15-17Upgrade Piper Jaffray Neutral → Overweight
Jun-22-17Resumed Jefferies Buy $17
Nov-01-16Downgrade Wedbush Outperform → Neutral $30 → $4
Oct-19-16Downgrade Piper Jaffray Overweight → Neutral
Dec-04-15Initiated Wells Fargo Outperform
Oct-23-15Resumed Jefferies Buy
May-03-13Initiated BioLogic Equity Research Sell
Feb-23-11Reiterated JMP Securities Mkt Outperform $9 → $12
Jul-29-10Reiterated Wedbush Outperform $12 → $13
Oct-19-09Initiated Brean Murray Sell $4
Oct-07-09Reiterated Leerink Swann Outperform $9 → $11
Aug-25-09Reiterated JMP Securities Mkt Outperform $13 → $15
Apr-14-09Downgrade Cantor Fitzgerald Buy → Hold
Oct-16-20 11:36AM  
Oct-07-20 06:45AM  
Oct-05-20 11:41AM  
Sep-28-20 08:30AM  
Sep-15-20 10:48AM  
Sep-11-20 08:30AM  
Sep-10-20 12:11PM  
Sep-02-20 04:15PM  
Sep-01-20 03:47PM  
Aug-20-20 09:43AM  
Aug-19-20 12:19PM  
Aug-10-20 08:30AM  
Aug-05-20 06:35PM  
Aug-03-20 12:49PM  
Jul-30-20 07:00AM  
Jul-29-20 04:15PM  
Jul-27-20 06:07PM  
Jul-09-20 07:43AM  
Jun-24-20 08:00AM  
Jun-19-20 12:22PM  
Jun-18-20 09:44AM  
Jun-16-20 08:36AM  
Jun-15-20 10:40PM  
Jun-14-20 06:00AM  
Jun-11-20 05:14PM  
May-29-20 09:00AM  
May-12-20 09:15AM  
May-11-20 05:15PM  
May-07-20 05:15PM  
May-05-20 11:30AM  
May-04-20 04:15PM  
Apr-29-20 07:14AM  
Apr-28-20 04:30PM  
Apr-21-20 07:00AM  
Apr-19-20 08:09AM  
Apr-17-20 08:30AM  
Apr-09-20 08:00AM  
Mar-09-20 01:37PM  
Mar-06-20 05:39AM  
Mar-05-20 08:27AM  
Mar-04-20 09:55AM  
Mar-02-20 08:30AM  
Feb-28-20 04:48PM  
Feb-27-20 04:06PM  
Feb-25-20 04:30PM  
Feb-20-20 12:31PM  
Feb-12-20 08:00AM  
Feb-04-20 05:29PM  
Jan-20-20 12:07PM  
Jan-16-20 10:34AM  
Jan-13-20 05:00AM  
Jan-09-20 08:30AM  
Dec-30-19 03:40PM  
Dec-24-19 09:30AM  
Dec-23-19 06:50AM  
Dec-17-19 06:45AM  
Dec-12-19 07:37PM  
Dec-09-19 06:45AM  
Dec-07-19 09:00AM  
Dec-06-19 09:33AM  
Dec-05-19 10:12AM  
Dec-04-19 09:29AM  
Dec-03-19 11:53AM  
Nov-26-19 08:30AM  
Nov-22-19 10:29AM  
Nov-19-19 10:08AM  
Nov-18-19 04:05PM  
Nov-14-19 10:59AM  
Nov-08-19 08:30AM  
Nov-06-19 05:15PM  
Nov-01-19 08:01AM  
Oct-30-19 04:15PM  
Oct-28-19 08:15PM  
Oct-01-19 01:01PM  
Sep-30-19 04:15PM  
Aug-30-19 08:30AM  
Aug-17-19 08:00AM  
Aug-14-19 09:02PM  
Aug-09-19 07:18AM  
Aug-08-19 06:00AM  
Aug-07-19 06:05PM  
Aug-06-19 04:05PM  
Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. Its therapeutic products that are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; ST-920 gene therapy for Fabry disease; ST-101 gene therapy for phenylketonuria; ST-400 and BIVV-003 for the treatment of hemoglobinopathies; SB-913 for the treatment of Mucopolysaccharidosis type II; SB-318 for the treatment of Mucopolysaccharidosis type I; and SB-FIX for the treatment of hemophilia B. The company has collaborative and strategic partnerships with Biogen Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DILLY STEPHEN GEORGEDirectorMar 19Option Exercise5.4235,000189,70040,000Mar 20 05:00 PM
DILLY STEPHEN GEORGEDirectorMar 19Sale6.0035,000210,0005,000Mar 20 05:00 PM
PARKER H STEWARTDirectorMar 18Buy5.203,00015,58513,000Mar 19 07:55 PM
Zakrzewski Joseph SDirectorMar 17Buy4.995,00024,95030,000Mar 19 05:00 PM
DILLY STEPHEN GEORGEDirectorMar 16Option Exercise5.4215,00081,30020,000Mar 18 09:09 PM
DILLY STEPHEN GEORGEDirectorMar 16Sale6.0215,00090,2615,000Mar 18 09:09 PM
Zakrzewski Joseph SDirectorMar 13Buy5.675,00028,35025,000Mar 13 05:41 PM
Zakrzewski Joseph SDirectorMar 12Buy6.3115,00094,65020,000Mar 13 05:41 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.